ANVISA Brazil CMC Requirements — Registration Dossier and Technical Requirements for Drug Products

Brazil is the largest pharmaceutical market in Latin America and one of the most exacting. ANVISA’s registration system has adopted the ICH CTD structure — but it has not adopted the ICH stability zone.

Brazil is classified as ICH climate Zone IVb, hot and humid, with a mean temperature near 30°C and 75% relative humidity, which means the ICH Q1A(R2) Zone II stability data supporting an FDA NDA or EMA MAA is not sufficient on its own for an ANVISA registration. A drug product stable for 36 months at 25°C/60% RH may not hold the same shelf life at 30°C/75% RH, and ANVISA expects 12-month Zone IVb long-term data at the time of registration approval. The company that discovers this when ANVISA issues an Exigência Técnica is well into a registration timeline that a concurrent Zone IVb stability arm would have shortened substantially.

ANVISA Zone IVb Stability — 30°C/75% RH Long-Term Requirement, 12-Month Data Minimum, and the Concurrent Stability Arm That Prevents a Multi-Year Registration Delay

ANVISA’s stability framework, governed by RDC 318/2019, applies to new, generic, and similar drug products and their active pharmaceutical ingredients, and requires stability testing conducted under the Zone IVb conditions that reflect Brazil’s actual climate rather than the temperate Zone II conditions ICH Q1A(R2) was originally built around for FDA and EMA submissions. The long-term condition ANVISA applies is 30°C ± 2°C at 75% RH ± 5% RH, with an accelerated condition of 40°C ± 2°C at 75% RH ± 5% RH, and where the accelerated condition shows significant change, an intermediate condition of 30°C ± 2°C at 65% RH ± 5% RH. The minimum stability data ANVISA expects at registration is 12 months at the Zone IVb long-term condition and 6 months at the accelerated condition, with significant change defined the same way as ICH Q1A(R2), a 5% shift from initial assay or a dissolution specification failure, just measured at the Zone IVb temperature rather than Zone II. The practical consequence for a program built only around an FDA-facing stability plan is direct: if the primary stability study was designed solely for 25°C/60% RH long-term and 40°C/75% RH accelerated conditions, and Brazil is a targeted launch market, a separate 30°C/75% RH long-term arm needs to start at the same time as the ICH primary study, in chambers actually calibrated to Zone IVb conditions. A registration dossier submitted with only Zone II data draws an Exigência Técnica requesting the Zone IVb dataset, and because that data has to be generated forward from whenever the arm is initiated, the delay is measured in the better part of a year or more rather than resolved with a written response alone.

PBBF and CBPF GMP Certification — Foreign Manufacturer Recognition, Cooperação Técnica Partner Authorities, and the PBBF Review Timeline

The Pasta Básica para Fabricante is ANVISA’s drug master file mechanism for API manufacturers, and it has to include the ANVISA GMP Certificate, the Certificado de Boas Práticas de Fabricação, along with the full manufacturing process description, API specification and analytical methods, and API stability data. For a foreign API manufacturer, that CBPF can be established one of two ways: through ANVISA’s own inspection of the facility, with certificates issued after a successful inspection typically valid for a defined period, or through recognition of a GMP certificate already issued by a Cooperação Técnica partner authority, which includes FDA, EMA member state national competent authorities, PMDA, Health Canada, TGA, and WHO GMP-listed authorities. An FDA Establishment Inspection Report confirming GMP compliance at a specific site isn’t automatically treated as equivalent to a CBPF on its own; it functions as supporting evidence within a formal recognition request rather than a substitute filing. The PBBF’s initial ANVISA review runs roughly 60 to 90 days before a CBPF is actually issued, and because the new drug registration dossier cannot cite a PBBF that hasn’t cleared that review, a foreign manufacturer’s GMP recognition pathway needs to be resolved well ahead of the planned registration filing date rather than treated as a parallel-track formality.

RDC 200/2017 Registration Framework, RDC 166/2017 Analytical Validation Format, and the RDC 31/2010 Dissolution Comparison Standard

ANVISA’s registration framework for new, generic, and similar drug products is established under RDC 200/2017, which standardizes the Technical Dossier structure and organizes the CTD-aligned submission content specifically to give ANVISA’s technical review teams a segregated, predictable dossier layout. Analytical method validation sits under a separate regulation, RDC 166/2017, which specifies Brazilian-specific validation parameters and a tabular presentation format that differs from the ICH Q2-based summary tables FDA and EMA accept: linearity requires a correlation coefficient of at least 0.99 across the validation range, accuracy is demonstrated at three concentration levels, commonly 80%, 100%, and 120% of the specification, with percent recovery expected within 98 to 102% for assay, and precision requires a relative standard deviation at or below 2.0% for assay repeatability. A validation package built entirely to the ICH Q2 summary format FDA and EMA accept, without recasting the data into RDC 166/2017’s specific tables, routinely draws an ANVISA request to re-present the same underlying data in the required format. For generic drug dissolution comparison specifically, ANVISA applies the same independent-model similarity factor methodology as FDA under RDC 31/2010, requiring the f2 similarity factor to fall between 50 and 100 for two dissolution profiles to be considered equivalent, the same threshold FDA applies rather than a materially stricter Brazilian-specific standard, meaning a generic dissolution package that clears the FDA f2 ≥50 bar under identical test conditions generally clears the equivalent ANVISA comparison as well.

The XGene ANVISA CMC Registration Architecture — Zone IVb Stability, PBBF/CBPF, RDC 166/2017 Validation, RDC 31/2010 Dissolution Comparison, and the Complete Brazil Registration CMC Strategy

The XGene ANVISA CMC Registration Architecture is a structured ANVISA registration CMC preparation strategy built around the recognition that a CMC package adapted for Brazil has to be re-built for ANVISA’s specific climate zone, validation format, and manufacturer recognition system, not simply translated from an FDA or EMA submission.

1. Zone IVb Stability Protocol Initiation — Start the 30°C/75% RH long-term stability arm at development batch manufacture, concurrent with the ICH Zone II primary stability program, ensuring 12-month data is available before the planned registration filing date. 2. PBBF and CBPF Preparation Timeline — Identify the API manufacturer’s GMP recognition pathway early: an existing ANVISA CBPF, a Cooperação Técnica partner authority certificate, or a new ANVISA inspection request, sequenced to clear the 60-to-90-day PBBF review well ahead of registration submission. 3. RDC 166/2017 Analytical Validation Format Adaptation — Recast ICH Q2-format validation data into the Brazilian-specific tabular structure for linearity, accuracy, and precision rather than submitting the FDA/EMA summary format as-is. 4. RDC 31/2010 Dissolution Comparison Verification — Confirm the generic dissolution package meets the f2 ≥50 similarity criterion under test conditions matched exactly to the reference product evaluation. 5. Exigência Técnica Response Readiness — Prepare Portuguese-language response infrastructure and anticipate the most common ANVISA deficiency patterns, missing Zone IVb data, missing CBPF, non-conforming validation format, before they’re raised.

The output is the ANVISA CMC registration strategy that treats Brazil’s Zone IVb climate, validation format, and manufacturer recognition requirements as planning inputs from the outset, rather than discoveries made through an Exigência Técnica.

ANVISA RDC 200/2017 establishes the Technical Dossier registration framework for new, generic, and similar drug products this article’s analysis is built around, while RDC 318/2019 establishes the Zone IVb stability testing requirement, 30°C/75% RH long-term and 40°C/75% RH accelerated, applied across those same product categories. RDC 166/2017 establishes the Brazilian-specific analytical method validation format, and RDC 31/2010 establishes the dissolution profile comparison methodology and the f2 ≥50 similarity criterion applied to generic drug registration.

For your ANVISA drug registration program, can you confirm today that a 30°C/75% RH Zone IVb long-term stability arm was initiated at the same time as your ICH Zone II primary stability study, that 12-month Zone IVb data will be available before your planned registration dossier submission, and that your API manufacturer’s PBBF review, whether through an existing CBPF or a Cooperação Técnica partner authority certificate, is on track to clear before that same filing date?